| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL4a1 |
| Uniprot No | P02462 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-167aa |
| 氨基酸序列 | GCAGSGCGKCDCHGVKGQKGERGLPGLQGVIGFPGMQGPEGPQGPPGQKGDTGEPGLPGTKGTRGPPGASGYPGNPGLPGIPGQDGPPGPPGIPGCNGTKGERGPLGPPGLPGFAGNPGPPGLPGMKGDPGEILGHVP |
| 预测分子量 | 39.9kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COL4A1重组蛋白的3篇参考文献示例(基于真实研究方向的概括，具体作者和标题为模拟示例)：
---
1. **标题**：*"COL4A1 mutations disrupt extracellular matrix secretion in a recombinant cell model"*
**作者**：Plaisier E, et al.
**摘要**：通过HEK293细胞表达携带致病突变的COL4A1重组蛋白，发现突变导致蛋白分泌障碍和细胞内滞留，揭示了COL4A1相关脑血管疾病的分子机制。
2. **标题**：*"Recombinant COL4A1 α1 chain characterization and its role in basement membrane assembly"*
**作者**：Sado Y, et al.
**摘要**：利用重组COL4A1蛋白研究IV型胶原网络的体外组装，证明其C端非胶原结构域对基底膜形成的关键作用，并阐明了突变导致的构象异常。
3. **标题**：*"Therapeutic potential of engineered COL4A1 protein in a mouse model of hereditary porencephaly"*
**作者**：Van Agtmael T, et al.
**摘要**：在小鼠模型中验证功能性重组COL4A1蛋白的治疗效果，结果显示其可部分恢复基底膜完整性并改善神经血管病理表型。
---
**注**：以上文献为示例，实际研究中建议通过PubMed或Google Scholar以关键词“COL4A1 recombinant”“COL4A1 expression”检索最新论文。如需具体文章，可提供研究方向以便进一步筛选。
The COL4A1 gene encodes the alpha-1 chain of type IV collagen, a critical component of basement membranes (BMs) that provide structural and functional support to tissues. As a major constituent of BMs, type IV collagen forms a flexible, sheet-like network through self-assembly and interactions with other BM proteins like laminins and nidogens. COL4A1 chains trimerize with COL4A2 chains to create heterotrimers, which are essential for BM integrity. Mutations in COL4A1 are linked to a spectrum of disorders, including hereditary angiopathy (HANAC syndrome), cerebrovascular abnormalities, kidney disease, and ocular defects, highlighting its role in vascular and epithelial tissue homeostasis.
Recombinant COL4A1 protein is engineered to study its structural and signaling functions. Produced via mammalian expression systems (e.g., HEK293 or CHO cells), it retains post-translational modifications critical for stability and interactions. Researchers use it to model BM assembly, investigate disease mechanisms caused by COL4A1 mutations (e.g., endoplasmic reticulum stress, impaired secretion), and develop therapeutic strategies. Its applications extend to tissue engineering, where it serves as a scaffold to mimic BM environments for cell culture or regenerative therapies. Additionally, recombinant COL4A1 aids in drug screening to identify compounds that rescue BM defects or stabilize mutant proteins. Challenges include replicating its complex quaternary structure and addressing mutation-specific effects. Ongoing studies focus on understanding its role in cell adhesion, migration, and mechanotransduction, as well as developing engineered variants for targeted therapies.
×
